Company intelligence / Profile preview
Viatris
Canonsburg, Pennsylvania, United Statesviatris.com ↗
- Ownership
- Public · VTRS
- Employees
- ~32000
- Development stage
- Other
01
Overview
Global pharmaceutical company formed through Mylan-Upjohn merger, focusing on access to medicines across therapeutic areas with ~1,400 approved molecules[6][10]. Recent strategic shifts include divestitures and ophthalmology/dermatology focus[2][5].
- Therapeutic areas
- PulmonologyCardiovascularOphthalmologyDermatologyInfectious Diseases
- Modalities
- Small moleculesBiosimilarsComplex genericsOTC products
- Industry
- Biotech
02
Drug pipeline
75 assets74 more assets in the full pipeline.
03
Partnerships
Biocon Biologics ($3.3B biosimilars deal)[2]Idorsia Pharmaceuticals (cenerimod collaboration)[9]Lexicon Pharmaceuticals (sotagliflozin agreement)[9]
04
Financials
- Market cap
- $21.8B
- Total revenue
- $14.3B
- Enterprise value
- $33.5B
Beyond the preview
Go deeper on Viatris.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viatris.